Software developer Synthace raises $25.6M to realize 'computer aided biology'
Although calls to turn biology into an engineering discipline have frequently been met with disdain and frustration by industry insiders, new players continue to emerge, undeterred, in search of ways to solve the notoriously inefficient process of drug development where things that work in labs often fail to work in humans.
Synthace, a London-based firm developing software for what it terms “computer aided biology,” wants to be at the forefront of that effort. And it now has $25.6 million in Series B cash to prove it can.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
